Patent classifications
C07F9/65306
Perfluorohydrocarbyl-N2-phosphinyl amidine compounds, chromium salt complexes, catalyst systems, and their use to oligomerize ethylene
A catalyst system comprising an N.sup.2-phosphinylamidine chromium salt complex having Structure PFHNPACr I: ##STR00001##
wherein Rf.sup.1, Rf.sup.2, Rf.sup.4, and Rf.sup.5 are independently selected from a perfluorohydrocarbyl group; and CrX.sub.p is a chromium salt; X is a monoanion, and p is an integer from 2 to 6. A process comprising a) contacting i) ethylene, ii) a catalyst system comprising an N.sup.2-phosphinylamidine chromium salt complex having Structure PFHNPACr I: ##STR00002##
wherein each Rf.sup.1, Rf.sup.2, Rf.sup.4, and Rf.sup.5 are independently selected from a perfluorohydrocarbyl group and CrX.sub.p is a chromium salt; X is a monoanion and p is an integer from 2 to 6, and iii) optionally an organic reaction medium; and b) forming an oligomer product in a reaction zone.
Heteroaryl compounds as inhibitors of TYK2, composition and application thereof
The present disclosure provides phosphonate-containing heterocycle compounds with TYK2 kinase inhibitory activity, pharmaceutical compositions comprising the same, and applications thereof. The present disclosure provides compounds of Formula (I), as inhibitors of TYK2 kinase. These compounds can be used for preventing and/or treating TYK2 kinase-related diseases and/or conditions.
##STR00001##
COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE
The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.
1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.